N Engl J Med·· 20 hours agoPickScore76
Long-Acting HIV Therapy in African Adults with Adherence Challenges.
Long-Acting HIV Therapy in African Adults with Adherence Challenges.
In brief
Long-acting injectable cabotegravir plus rilpivirine every 8 weeks maintained viral suppression in African adults with HIV and adherence challenges, matching daily oral dolutegravir-based therapy. At week 48, 91.0% of the long-acting group (244 of 268) had a viral load below 50 copies per milliliter versus 89.2% of the oral group (240 of 269), meeting noninferiority. Confirmed virologic failure occurred in 5 participants (1.9%) on long-acting therapy and none on oral therapy.
Why it matters
It tests long-acting injectable HIV therapy in the population most affected by adherence failure: African adults with suboptimal adherence.
Source: N Engl J Med · doi.org